Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1 of SPC). 
Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease. 
1. Volibris Summary of Product Characteristics (SPC). Available at http://www.medicines.ie/medicine/15338/SPC/Volibris+5+mg+and+10+mg+film-coated+tablets/. Last Accessed - February 2017.